NCT06799520进行中（未招募）1 期
A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)
Otsuka Pharmaceutical Development & Commercialization, Inc.6 个研究点 分布在 4 个国家目标入组 30 人开始时间: 2025年3月17日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 6
- 主要终点
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) Graded by Severity
研究概览
简要总结
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s). The total duration of the clinical trial for each participant will be up to approximately 9 to 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Estimated glomerular filtration rate (eGFR) >30 milliliters/minute/1.73 square meters (mL/min/1.73 m^2) at the screening visit.
- •For SLE participants:
- •Participant has a confirmed diagnosis of SLE according to European League Against Rheumatism/American College of Rheumatology SLE classification criteria ≥ 24 weeks prior to signing the informed consent form (ICF).
- •For AA participants:
- •Current scalp involvement between 25% and 95%, inclusive (Severity of Alopecia Tool [SALT] score between 25 and 95, inclusive), at screening.
- •Current episode of AA is of duration > 24 weeks (without evidence of spontaneous terminal hair regrowth at the time of screening and first treatment, i.e., no more than 10% regrowth), but ≤ 5 years from onset of current episode of severe scalp hair loss.
- •For FSGS participants:
- •Prior biopsy (no time limit) showing histologic minimal change disease (MCD), FSGS, or MCD/FSGS spectrum.
- •History of at least one prior episode of nephrotic syndrome, defined as 24-hour urine protein > 3.5 grams per day (g/day) and serum albumin < 3.5 grams per deciliter (g/dL).
- •History of steroid responsive nephrotic syndrome, including participants who achieved complete remission, partial remission, had a course of steroid dependent nephrotic syndrome or relapsing nephrotic syndrome (all defined as per the managing physician at the time of the episode).
排除标准
- •Receipt of high-dose corticosteroid therapy within 4 weeks prior to screening as either (a) intravenous (IV) pulse corticosteroid therapy or (b) daily oral corticosteroid therapy of ≥ 1 milligrams per kilogram (mg/kg) or up to 40 milligrams per day (mg/day) prednisone (or equivalent).
- •Receipt of blood products within 6 months prior to screening.
- •Previous exposure to VIS171 or any other drug targeting interleukins (IL)-2 or the IL-2 receptor or T regulatory cells.
- •History of or current diagnosis of catastrophic or severe anti-phospholipid syndrome (APS) within 1 year prior to signing ICF. SLE participants with APS adequately controlled by anticoagulant are eligible. SLE participants who are found to be triple positive for anti-phospholipid antibodies at screening (without clinical APS) will be excluded unless they are on stable anti-thrombotic therapy.
- •Known primary immunodeficiency disorder.
- •Participant has a history of Class V lupus nephritis.
- •Receipt of anifrolumab, tumor necrosis factor-alpha monoclonal antibodies ([TNF]-α mAb), immunoglobulins (IV/SC) plasmapheresis, or any other immunosuppressants (calcineurin inhibitors, Janus kinase [JAK] inhibitors or other kinase inhibitors), other than hydroxychloroquine, mycophenolic acid (MPA)/mycophenolate mofetil (MMF) and corticosteroids, within 6 months prior to screening.
- •Participant has concomitant hair loss of another form, including but not limited to traction alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, or androgenetic alopecia.
- •Participant has received (1) Within 12 weeks prior to Day 1: Systemic therapies (oral or injection), such as corticosteroids, JAK inhibitors, methotrexate, calcineurin inhibitors, oral minoxidil, low-dose IL-2 and topical immunotherapies such as psoralen plus UVA (PUVA) , diphenylcyclopropenone (DPCP), dinitrochlorobenzene (DNCB), intralesional steroids or (2) Within 4 weeks prior to Day 1: Other topical therapies, such as topical minoxidil, clobetasol etc. These therapies will also not be allowed during this trial.
- •Steroid resistant nephrotic syndrome defined as absence of history of at least 1 episode of complete or partial remission following at least 12 weeks of full dose corticosteroid therapy.
- •Receipt of anifrolumab, TNF-α mAb, immunoglobulins (IV/SC) plasmapheresis, or any other immunosuppressants (JAK inhibitors or other kinase inhibitors).
- •Note: Other protocol-specified Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
VIS171
Experimental
Participants will receive VIS171 dose via SC injection, from Week 1 to Week 21.
干预措施: VIS171 (Drug)
结局指标
主要结局
Number of Participants with Treatment Emergent Adverse Events (TEAEs) Graded by Severity
时间窗: From first dose of the study drug up to end of the study (up to Week 45)
次要结局
- Change from Baseline in Absolute Number of Regulatory T (Treg) Cells, Total T Helper Cells, Cytotoxic T Cells, and Natural Killer Cells in Blood(From baseline up to Week 21)
- Percent Change from Baseline in Treg Cells/CD4+ Cells, Total T Helper Cells, Cytotoxic T Cells, and Natural Killer Cells in Blood(From baseline up to Week 21)
- Serum Concentration of VIS171 Over Time(Up to Week 21)
- Number of Participants with Confirmed Positive or Negative Anti-drug Antibody (ADA) Titers(Up to Week 21)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult VolunteersChronic Stable IllnessHealthyNCT05181683Regeneron Pharmaceuticals45
进行中（未招募）
1 期
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With VitiligoVitiligoNCT06625177Teva Branded Pharmaceutical Products R&D LLC66
招募中
1 期
Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.Advanced Solid Tumors Harboring MAPK Pathway AlterationsNCT05488821Qilu Pharmaceutical Co., Ltd.40
已完成
1 期
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes MellitusType 1 Diabetes MellitusNCT03162926ViaCyte3
已完成
1 期
Phase I Study on VEGF Vaccination in Metastatic Solid TumorsMetastatic CancerNCT02237638Amsterdam UMC, location VUmc30